Voyager Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Voyager Therapeutics
VYGR Stock  USD 3.89  0.01  0.26%   
Voyager Therapeutics financial statements provide useful quarterly and yearly information to potential Voyager Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Voyager Therapeutics financial statements helps investors assess Voyager Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Voyager Therapeutics' valuation are summarized below:
Gross Profit
-47.4 M
Profit Margin
(0.81)
Market Capitalization
214.8 M
Enterprise Value Revenue
0.1431
Revenue
80 M
There are over one hundred nineteen available fundamental trend indicators for Voyager Therapeutics, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to double-check Voyager Therapeutics' current fundamental performance against the performance between 2010 and 2025 to make sure the trends are evolving in the right direction. As of 03/19/2025, Market Cap is likely to drop to about 231.7 M. In addition to that, Enterprise Value is likely to drop to about 202 M

Voyager Therapeutics Total Revenue

73.32 Million

Check Voyager Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Voyager Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.5 M, Selling General Administrative of 27.2 M or Gross Profit of 55.6 M, as well as many indicators such as Price To Sales Ratio of 3.88, Dividend Yield of 0.0 or PTB Ratio of 1.04. Voyager financial statements analysis is a perfect complement when working with Voyager Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Voyager Therapeutics Correlation against competitors.
To learn how to invest in Voyager Stock, please use our How to Invest in Voyager Therapeutics guide.

Voyager Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets229.7 M393.1 M171 M
Slightly volatile
Short and Long Term Debt Total30.6 M43.7 M24.9 M
Slightly volatile
Other Current Liabilities10.8 M14.2 M8.1 M
Slightly volatile
Total Current Liabilities39.6 M49.8 M30.2 M
Slightly volatile
Accounts Payable4.2 M4 M1.6 M
Slightly volatile
Cash64.2 M71.4 M47.8 M
Slightly volatile
Non Current Assets Total122.1 M116.2 M34.4 M
Slightly volatile
Other Assets1.091.15751.6 K
Slightly volatile
Cash And Short Term Investments178.1 M266.7 M132.6 M
Slightly volatile
Common Stock Shares Outstanding32.5 M57.7 M24.3 M
Slightly volatile
Liabilities And Stockholders Equity229.7 M393.1 M171 M
Slightly volatile
Non Current Liabilities Total59.7 M43.5 M45.1 M
Slightly volatile
Total Liabilities98.9 M93.3 M74.4 M
Slightly volatile
Total Current Assets190.4 M276.8 M141.8 M
Slightly volatile
Short Term Debt4.9 M7.2 M3.9 M
Slightly volatile
Other Liabilities8.1 M8.6 M29.7 M
Very volatile
Property Plant And Equipment Net31.1 M47.7 M22.1 M
Slightly volatile
Common Stock Total Equity32.5 K43.7 K24 K
Slightly volatile
Short Term Investments100 M195.3 M132.9 M
Slightly volatile
Other Current Assets9.1 M8.6 M2.8 M
Slightly volatile
Property Plant And Equipment Gross33.9 M63.6 M24 M
Slightly volatile
Short and Long Term Debt5 M5.7 M6.2 M
Slightly volatile
Common Stock36.5 K55 K25.3 K
Slightly volatile
Property Plant Equipment18.2 M20.5 M13.5 M
Slightly volatile
Current Deferred Revenue30.9 M24.4 M25.6 M
Slightly volatile
Net Receivables1.4 M1.5 M7.6 M
Slightly volatile
Capital Surpluse384.1 M520.6 M327.9 M
Slightly volatile
Non Current Liabilities Other950 K1000 K10.1 M
Slightly volatile
Net Invested Capital154.6 M299.8 M138.6 M
Slightly volatile
Net Working Capital179.6 M227 M161.1 M
Pretty Stable
Capital Stock44.2 K55 K36.3 K
Slightly volatile
Capital Lease Obligations28.4 M43.7 M34.3 M
Very volatile

Voyager Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization3.5 M5.1 M4.1 M
Pretty Stable
Selling General Administrative27.2 M35.9 M20.8 M
Slightly volatile
Other Operating Expenses99.9 M163.3 M75.8 M
Slightly volatile
Research Development72.7 M127.4 M55 M
Slightly volatile
Cost Of Revenue4.9 M5.1 M34.2 M
Pretty Stable
Total Operating Expenses99.5 M163.3 M74.6 M
Slightly volatile
Interest Income364.9 K384.1 K1.1 M
Pretty Stable
Reconciled Depreciation4.2 M4.7 M2.9 M
Slightly volatile

Voyager Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Cashflows From Financing Activities1.2 M1.2 M19.1 M
Pretty Stable
Total Cash From Financing Activities119.7 M114 M40.1 M
Slightly volatile
End Period Cash Flow65.2 M74.2 M48.6 M
Slightly volatile
Sale Purchase Of Stock10.3 M17.4 M9.8 M
Very volatile
Stock Based Compensation11.3 M14.8 M7.9 M
Slightly volatile
Begin Period Cash Flow63.8 M70.4 M43.9 M
Slightly volatile
Depreciation3.2 M4.7 M2.3 M
Slightly volatile
Change To Netincome12.7 M11.2 M9.3 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3.884.087110.1325
Very volatile
Days Sales Outstanding6.526.861922.653
Pretty Stable
Stock Based Compensation To Revenue0.180.18480.3743
Very volatile
Capex To Depreciation0.710.74426.5327
Slightly volatile
EV To Sales3.553.74168.3709
Very volatile
Payables Turnover2.372.4938.149
Pretty Stable
Sales General And Administrative To Revenue0.430.4490.8797
Very volatile
Research And Ddevelopement To Revenue2.91.59212.3322
Very volatile
Capex To Revenue0.04180.0440.126
Very volatile
Cash Per Share8.674.62456.5044
Very volatile
Days Payables Outstanding12511958.2213
Slightly volatile
Current Ratio6.135.55984.5643
Slightly volatile
Receivables Turnover55.8553.192236.7511
Very volatile
Capex Per Share0.0580.06110.1616
Slightly volatile
Revenue Per Share1.771.38732.7836
Slightly volatile
Interest Debt Per Share1.340.75822.1472
Slightly volatile
Debt To Assets0.110.11125.0276
Slightly volatile
Graham Number11.6517.5512.0939
Slightly volatile
Days Of Payables Outstanding12511958.2213
Slightly volatile
Ebt Per Ebit1.140.77251.042
Pretty Stable
Long Term Debt To Capitalization0.120.10850.3404
Slightly volatile
Quick Ratio6.175.55984.5981
Slightly volatile
Net Income Per E B T0.781.01030.9735
Slightly volatile
Cash Ratio1.431.43341.4397
Slightly volatile
Days Of Sales Outstanding6.526.861922.653
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.211.231.1423
Slightly volatile
Fixed Asset Turnover2.061.67853.4092
Slightly volatile
Debt Ratio0.110.11125.0276
Slightly volatile
Price Sales Ratio3.884.087110.1325
Very volatile
Asset Turnover0.210.20350.1969
Slightly volatile

Voyager Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap231.7 M327 M239.9 M
Slightly volatile
Enterprise Value202 M299.3 M210.1 M
Slightly volatile

Voyager Fundamental Market Drivers

Cash And Short Term Investments266.7 M

Voyager Upcoming Events

5th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
5th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Voyager Therapeutics Financial Statements

Voyager Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Voyager Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Voyager Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Voyager Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue24.4 M30.9 M
Cost Of Revenue5.1 M4.9 M
Total Revenue80 M73.3 M
Stock Based Compensation To Revenue 0.18  0.18 
Sales General And Administrative To Revenue 0.45  0.43 
Research And Ddevelopement To Revenue 1.59  2.90 
Capex To Revenue 0.04  0.04 
Revenue Per Share 1.39  1.77 
Ebit Per Revenue(1.04)(1.09)

Pair Trading with Voyager Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Voyager Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Voyager Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Voyager Stock

  0.83ME 23Andme HoldingPairCorr

Moving against Voyager Stock

  0.85VALN Valneva SE ADRPairCorr
  0.62DVAX Dynavax TechnologiesPairCorr
  0.55DMAC DiaMedica TherapeuticsPairCorr
  0.55VIGL Vigil NeurosciencePairCorr
  0.52EQ EquilliumPairCorr
The ability to find closely correlated positions to Voyager Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Voyager Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Voyager Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Voyager Therapeutics to buy it.
The correlation of Voyager Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Voyager Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Voyager Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Voyager Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Voyager Stock Analysis

When running Voyager Therapeutics' price analysis, check to measure Voyager Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Voyager Therapeutics is operating at the current time. Most of Voyager Therapeutics' value examination focuses on studying past and present price action to predict the probability of Voyager Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Voyager Therapeutics' price. Additionally, you may evaluate how the addition of Voyager Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY